Natural killer cells plus immunotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have small cell lung cancer that has spread to other parts of the body (extensive stage).
- Completed 4 cycles of platinum chemotherapy plus immunotherapy, and the cancer has not grown (stable, partial, or complete response).
- Be physically active and able to care for yourself (ECOG score 0-2).
- Have adequate organ function (bone marrow, liver, kidneys).
- Not have active brain metastases, autoimmune diseases, or other serious uncontrolled conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This trial combines standard chemotherapy and radiation with two immunotherapy drugs (immune checkpoint inhibitors) to see if they work better together for people with limited-stage small cell lung cancer. It aims to improve outcomes without using strong immune-suppressing medicines.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This study tests a natural killer (NK) cell therapy combined with standard maintenance treatment for people with certain advanced cancers (non-small cell lung, colorectal, liver, or stomach cancer) that have not progressed after first-line therapy. It is for people who have completed initial treatment and whose disease is stable or responding.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.